2 active not recruiting, 1 completed, 1 not yet recruiting, 1 recruiting. 6 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Active not recruiting 2, Completed 1, Not yet recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Neoadjuvant Therapy: new trials by email Literature Review of Neoadjuvant Therapy trials Research Report on Neoadjuvant Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study Observation without surgery, Standard-of-care surgery - Non-Small Cell Lung Cancer, Immunotherapy | Phase 1 | Not yet recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 14 | 2026-10-01 | 2026-08-14 |
| A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma Tislelizumab, FLOT Chemotherapy - Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma | Phase 1 | Recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 18 | 2025-12-12 | 2025-12-19 |
| A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma Tislelizumab, Afatinib, Lysogenic HSV virus. - HNSCC, Lysogenic HSV Virus | Phase 1 / Phase 2 | Active not recruiting | West China Hospital | 29 | 2025-06-10 | 2026-07-01 |
| A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus Lysogenic HSV virus., Tislelizumab, Afatinib - HNSCC, Lysogenic HSV Virus | Phase 1 | Withdrawn | West China Hospital | 2024-12-15 | 2026-10-16 | |
| Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC PD-1 inhibitor+ Gemcitabine + Cisplatin - Locally Advanced Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 1 | Active not recruiting | Fifth Affiliated Hospital, Sun Yat-Sen University | 20 | 2020-12-15 | 2026-09-09 |
| Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas DNX-2401 - Brainstem Glioma, Neoadjuvant Therapy | Phase 1 | Completed | Clinica Universidad de Navarra, Universidad de Navarra | 12 | 2017-05-26 | 2023-04-06 |
Squamous Cell Carcinoma of Head and Neck (3) · Adenocarcinoma Of Esophagus (1) · Carcinoma, Non-Small-Cell Lung (1) · Pathologic Complete Response (1) · Stomach Neoplasms (1)
Neoplasms (5) · Neoplasms by Site (5) · Carcinoma (3) · Carcinoma, Squamous Cell (3) · Head and Neck Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Disease Attributes (1) · Disease Progression (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1)
tislelizumab (3) · Afatinib (2) · Biological Factors (2) · Immunotherapy (2) · Cisplatin (1) · Observation (1) · Surgical Procedures, Operative (1) · toripalimab (1)
West China Hospital (2) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Clinica Universidad de Navarra, Universidad de Navarra (1) · Fifth Affiliated Hospital, Sun Yat-Sen University (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1)
China (3) · Canada (1) · Germany (1) · Spain (1)
Xingchen Peng (2) · Antoine Desilets, MD, MSc (1) · Florian Lordick, Prof. Dr. (1) · Jaime Gallego, MD, PhD (1) · Salah Eddin Al-Batran, Prof. Dr. (1) · Zhigang Liu, M.D. (1)
PMID 17848677, PMID 18089777, PMID 24903904, PMID 29658848, PMID 31138805, PMID 35767439
2025 (1)